Search Results

• • 35 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Pfizer COVID vaccine protects against worrying coronavirus variants.

  Author:Ewen CallawayFrom:Nature (Vol. 593, Issue 7859) Peer-Reviewed

  May 20, 20211,070 words Article 1490LData from Qatar provide strongest evidence yet that COVID-19 vaccines can stop strains thought to pose a threat to immunization efforts. Data from Qatar provide strongest evidence yet that COVID-19 vaccines can stop...

• Data 'reassuring' on COVID-19 vaccines in pregnancy: Rates of complications are not significantly different from those of unvaccinated.

  Author:Laird HarrisonFrom:Family Practice News (Vol. 51, Issue 4)

  Apr. 2021970 words Article 1360LPregnant women can safely get vaccinated with the Pfizer-Bio-NTech and Moderna vaccines for COVID-19, surveillance data from the Centers for Disease Control and Prevention suggest. More than 30,000 women who received...

• Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2.

  Authors:Mohd Zulkifli Salleh, Mohd Nor Norazmi, and Zakuan Zainy DerisFrom:PeerJ (Vol. 10) Peer-Reviewed

  Mar. 9, 202216,689 words Article 1570LSince the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) in late 2019, hundreds of millions of people have been infected worldwide....

• Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors.

  Authors:Evangelos Terpos, Flora Zagouri, Michalis Liontos, Aimilia D. Sklirou, Konstantinos Koutsoukos, Christos Markellos, et al.From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-Reviewed

  May 31, 20211,256 words Article 1360LVaccination for SARS-CoV-2 provides significant protection against the infection in the general population. However, only limited data exist for patients with cancer under systemic therapy. Based on this, our site has...

• Results of the RENAISSANCE Study: Response to BNT162b2 COVID-19 vacciNe--short- And long-term Immune reSponSe evAluatioN in health Care workErs.

  Authors:Arianna Pani, Valeria Cento, Chiara Vismara, Daniela Campisi, Federica Di Ruscio, Alessandra Romandini, et al.From:Mayo Clinic Proceedings (Vol. 96, Issue 12) Peer-Reviewed

  Dec. 20215,489 words Report 1640LObjective: To evaluate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) anti-spike (S) IgG antibody production alter vaccination with BNT162b2 and the protection from symptomatic breakthrough infections...

• Every T. rex, COVID asthma drug and variant control.

  From:Nature (Vol. 592, Issue 7855) Peer-Reviewed

  Apr. 22, 2021862 words Article 1280LThe latest science news, in brief. The latest science news, in brief. Author Affiliations: Every T. rex , COVID asthma drug and variant control Fossils, such as this skeleton of a T. rex on display in the...

• Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients.

  Authors:Mathieu Leclerc, Rabah Redjoul, Anne Le Bouter, Florence Beckerich, Christine Robin, Vincent Parinet, et al.From:Journal of Hematology & Oncology (Vol. 15, Issue 1) Peer-Reviewed

  Mar. 18, 20222,580 words Article 1720LHematopoietic stem cell transplant (HSCT) recipients are at high-risk for severe COVID-19 and have altered immune responses to vaccination. We sought to evaluate the dynamics of immune response to BNT162b2 mRNA vaccine...

• Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study.

  Authors:Jingxin Li, Aimin Hui, Xiang Zhang, Yumei Yang, Rong Tang, Huayue Ye, et al.From:Nature Medicine (Vol. 27, Issue 6) Peer-Reviewed

  June 202110,135 words Report 1650LAn effective vaccine is needed to end the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Here, we assess the preliminary safety, tolerability and immunogenicity data from an ongoing single-center...

• Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution.

  Authors:Fulvia Pimpinelli, Francesco Marchesi, Giulia Piaggio, Diana Giannarelli, Elena Papa, Paolo Falcucci, et al.From:Journal of Hematology & Oncology (Vol. 14, Issue 1) Peer-Reviewed

  May 17, 20216,274 words Report 1510LBackground Safety and immunogenicity of BNT162b2 mRNA vaccine are unknown in hematological patients; both were evaluated prospectively in 42 patients with multiple myeloma (MM) and 50 with myeloproliferative...

• Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study.

  Authors:Wei Kang, Jessica J. P. Shami, Vincent K. C. Yan, Xuxiao Ye, Joseph E. Blais, Xue Li, et al.From:Journal of Hematology & Oncology (Vol. 15, Issue 1) Peer-Reviewed

  May 19, 20223,033 words Clinical report 1350LBackground The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in...

• SARS-CoV-2: vaccines in the pandemic era.

  Authors:Dan-Dan Li and Qi-Han LiFrom:Military Medical Research (Vol. 8, Issue 1) Peer-Reviewed

  Jan. 6, 20218,329 words Article 1500LCoronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has caused millions of infections and deaths worldwide since its emergence in December 2019. As there is...

• The UK has approved a COVID vaccine -- here's what scientists now want to know.

  Authors:Heidi Ledford, David Cyranoski, and Richard Van NoordenFrom:Nature (Vol. 588, Issue 7837) Peer-Reviewed

  Dec. 10, 20202,114 words Article 1310LThe Pfizer-BioNTech vaccine has passed safety and efficacy tests -- but researchers still have many questions about how this and other vaccines will perform as they're rolled out to millions of people. The...

• Comparison of Symptoms and Antibody Response Following Administration of Moderna or Pfizer SARS-CoV-2 Vaccines.

  Authors:Michael T. Kelliher, Joshua J. Levy, Robert D. Nerenz, Bradley Poore, Abigail A. Johnston, Amanda R. Rogers, et al.From:Archives of Pathology & Laboratory Medicine (Vol. 146, Issue 6) Peer-Reviewed

  June 20226,651 words Report 1690L* Context.--Moderna (mRNA-1272) and Pfizer (BNT162b2) SARS-CoV-2 vaccines demonstrate favorable safety and efficacy profiles, but direct comparison data are lacking. Objective.--To determine the vaccines' side effect...

• Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection.

  Authors:Nick K Jones, Lucy Rivett, Shaun Seaman, Richard J Samworth, Ben Warne, Chris Workman, et al.From:eLife (Vol. 10) Peer-Reviewed

  Apr. 8, 202110,817 words Article 1440LThe BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech) is being utilised internationally for mass COVID-19 vaccination. Evidence of single-dose protection against symptomatic disease has encouraged some countries to opt...

• US authorization of first COVID vaccine marks new phase in safety monitoring.

  Author:Heidi LedfordFrom:Nature (Vol. 588, Issue 7838) Peer-Reviewed

  Dec. 17, 20201,186 words Article 1390LThe FDA has issued an emergency-use authorization for the Pfizer-BioNTech vaccine. Regulators are gearing up to look for side effects. The FDA has issued an emergency-use authorization for the Pfizer-BioNTech vaccine....

• Effect of the third dose of BNT162b2 vaccine on quantitative SARS-CoV-2 spike 1-2 IgG antibody titers in healthcare personnel.

  Authors:Maria Elena Romero-Ibarguengoitia, Diego Rivera-Salinas, Yodira Guadalupe Hernández-Ruíz, Ana Gabriela Armendariz-Vázquez, Arnulfo González-Cantú, Irene Antonieta Barco-Flores, et al.From:PLoS ONE (Vol. 17, Issue 3) Peer-Reviewed

  Mar. 2, 20224,990 words Report 1460LBackground Vaccination is our main strategy to control SARS-CoV-2 infection. Given the decrease in quantitative SARS-CoV-2 spike 1-2 IgG antibody titers three months after the second BNT162b2 dose, healthcare workers...

• Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January-May 2021, Aragon, Spain.

  Authors:Alicia del Cura-Bilbao, Hector Lopez-Mendoza, Armando Chaure-Pardos, Alberto Vergara-Ugarriza, and Joaqurn Guimbao-BescosFrom:Emerging Infectious Diseases (Vol. 28, Issue 3) Peer-Reviewed

  Mar. 20224,617 words Report 1560LReducing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission is a worldwide challenge; widespread vaccination could be one strategy for control. We conducted a prospective, population-based cohort...

• Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.

  Authors:Meghan E Garrett, Jared G Galloway, Caitlin Wolf, Jennifer K Logue, Nicholas Franko, Helen Y Chu, et al.From:eLife (Vol. 11) Peer-Reviewed

  Jan. 24, 202211,348 words Article 1510LBackground: Control of the COVID-19 pandemic will rely on SARS-CoV-2 vaccine-elicited antibodies to protect against emerging and future variants; an understanding of the unique features of the humoral responses to...

• COVID-19 vaccine BNT162b1 elicits human antibody and T.sub.H1 T cell responses.

  Authors:Ugur Sahin, Alexander Muik, Evelyna Derhovanessian, Isabel Vogler, Lena M. Kranz, Mathias Vormehr, et al.From:Nature (Vol. 586, Issue 7830) Peer-Reviewed

  Oct. 22, 20209,730 words Clinical report 1550LAn effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing...

• mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.

  Authors:Zijun Wang, Fabian Schmidt, Yiska Weisblum, Frauke Muecksch, Christopher O. Barnes, Shlomo Finkin, et al.From:Nature (Vol. 592, Issue 7855) Peer-Reviewed

  Apr. 22, 202110,562 words Clinical report 1570LHere we report on the antibody and memory B cell responses of a cohort of 20 volunteers who received the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccine against SARS-CoV-2.sup.1-4. Eight weeks after the second...